Aurora Spine Corporation has announced a joint marketing agreement for the DEXA platform with Echolight Medical of the Canadian Business Journal.

Carlsbad, CA, February 24, 2022 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or “Company”) (TSXV: ASG) (OTCQB: ASAPF), an innovative spinal implant manufacturer today Has entered into a co-marketing agreement with Echolight Medical, a manufacturer of radiation-free EchoS portable densitometers used to evaluate the quality of bone mineral density (BMD) and BMD-independent bone microarchitecture.

Aurora develops and manufactures spinal implants based on DEXA technology, and Echolight is engaged in the bone health assessment business without ionizing radiation. As part of the Aurora DEXA platform, the two companies have agreed to promote each other’s products to their respective customers and prospects.

Through this mutual effort, Aurora will be able to combine Echolight’s bone health assessment capabilities with a unique DEXA technology-based patient-friendly implant, and Echolight will sell and promote Echolight’s devices to sell and promote Aurora’s DEXA technology implants. You can determine which of these is best suited for each patient’s bone quality, normality, and osteopenia. Or osteoporosis.

Trent Northcutt, CEO and President of Aurora Spine, said: This collaborative effort will enable patients to access a one-stop shop for patient-appropriate implants based on rapid and accurate real-time bone quality analysis with out-of-the-box reports. We are confident that our partnership and common passion will expand medical access to more people. “

Doug Tefft, President of Echolight, said: “We are pleased to contribute to Aurora’s innovative DEXA platform, which allows Echolight to provide support for orthopedic and spinal treatment in addition to osteoporotic bone health assessments. Echolight devices are widespread in Europe. Used and recently launched in the United States. Echolight is a critical clinical combination of a portable, radiation-free device in the United States combined with the only patented, FDA-approved bone-compatible fusion device. We look forward to a positive impact, “said Doug Tefft, President of Echolight USA. “I am honored to be able to work with the Aurora team in the spine and orthopedic fixation field.”

Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, said: Percentage of patients with spinal disorders requiring fusion surgery. We believe that mutual efforts with the Echolight team will bring new solutions to the market and improve standard of care for patients. “

About Echo light

Echolight Medical has developed the first clinically available method for direct non-ionizing measurements of bone mineral density (BMD) of the lumbar spine and femur.

The device Echo S utilizes proprietary REMS (Radiofrequency Echographic Multi Spectrometry) technology to scan the lumbar spine and proximal femur. EchoS quickly generates medical reports containing BMD, T-scores, and Z-scores. In addition, the system automatically assesses the quality of bone microarchitecture independently of BMD and provides a 5-year probability of major osteoporotic fractures.

EchoS offers significantly improved levels of accuracy, sensitivity to changes in bone mass, and diagnostic reproducibility over DXA systems. This, coupled with the absence of ionizing radiation, allows the diagnosis of osteoporosis at a broader and earlier stage in terms of care. It also enables more accurate monitoring after diagnosis. For more information on FDA-approved Echo S, please visit

About Aurora Spine

Aurora Spine focuses on bringing new solutions to the spinal implant market through a range of innovative, minimally invasive regenerative spine implant technologies. Additional information can be accessed at or

Neither the TSX Venture Exchange nor its regulatory service provider (the term is defined in the TSX Venture Exchange Policy) is responsible for the validity or accuracy of this release.

Description of future prospects

This news release contains future prospects, including but not limited to those described in “Risk Factors” and “Notes on Future Prospects”, including substantive known and unknown risks and uncertainties. Contains information about. “Information” in Aurora Spine’s final prospectus (collectively, “information about the future outlook”). Information on the future outlook for this news release includes information on the proposed use and success of the company’s products in surgery. Aurora Spine warns investors of Aurora Spine securities about key factors that could cause actual results of Aurora Spine to differ significantly from those predicted in the forward-looking statements contained in this news release. .. Expectations, beliefs, plans, objectives, assumptions, or statements that represent or discuss future events or achievements are forward-looking, not historical facts, and may cause actual results or consequences. May be accompanied by some estimates, assumptions, and uncertainties. One-sidedly different from what was stated in such forward-looking statements. There is no guarantee that the expectations set forth here will be proven to be correct. Therefore, future investors should not place undue reliance on these forward-looking statements. These statements are made only as of the date of this press release and Aurora Spine undertakes no obligation to update or revise them to reflect new events or circumstances.

contact address:

Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Claus
(760) 424-2004

Adam Lowensteiner
Phoenix | New York
Phone: 646-829-9700

Echo Light Contact:
Doug Tefft
President – ​​Echolight Medical USA
(425) 503-4840

CBJ News Maker

Aurora Spine Corporation has announced a joint marketing agreement for the DEXA platform with Echolight Medical of the Canadian Business Journal.

Source link Aurora Spine Corporation has announced a joint marketing agreement for the DEXA platform with Echolight Medical of the Canadian Business Journal.

Related Articles

Back to top button